PMA device
Advia Centaur Psa Assay
Siemens Healthcare Diagnostics · Total, Prostate Specific Antigen (Noncomplexed & Complexed) For Detection Of Prostate Cancer (MTF, Class III) · First FDA decision Oct 15, 2012, newest Jul 27, 2017Prostate cancer
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
PMA pathway
Device trials
0
Naming "Advia Centaur Psa"
MAUDE reports
3
Brand "Advia Centaur Psa", since 2015
PubMed studies
0
Mentioning "Advia Centaur Psa"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Advia Centaur Psa Assay
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
- ADVIA CENTAUR PSA ASSAYPMA supplement
P950021-S014 · Decided Jul 27, 2017 · 812 days after receipt · Normal 180 Day Track
Device type: Total, prostate specific antigen (noncomplexed & complexed) for detection of prostate cancer (MTF) · Laboratory Medicine & Pathology
- ADVIA CENTAUR PSA ASSAYPMA supplement
P950021-S013 · Decided Oct 15, 2012 · 203 days after receipt · Normal 180 Day Track No User Fee
Device type: Total, prostate specific antigen (noncomplexed & complexed) for detection of prostate cancer (MTF) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Prostate Specific AntigenNational determinationOn the books190.31Updated Oct 1, 2026
- Prostate Specific Antigen (Inclusion of ICD-9-CM Code 600.01 for BPH with Urine Obstruction)Coding analysisReview closedCAG-00232NUpdated Sep 15, 2026
- Prostate Specific Antigen (Addition of ICD-9-CM 600.00, Hypertrophy (benign) of Prostate Without Urinary Obstruction, as a covered indication)Coding analysisReview closedCAG-00326NUpdated Sep 15, 2026
- Prostate Cancer Detection with IsoPSA®Local determinationIn effectL39284CGS Administrators, LLCUpdated Oct 30, 2026
- Autologous Cellular Immunotherapy Treatment of Metastatic Prostate CancerNational analysisReview closedCAG-00422NUpdated Nov 19, 2026
- Abarelix for the Treatment of Prostate CancerNational analysisReview closedCAG-00238NUpdated Sep 15, 2026
- Cryosurgical Salvage Therapy for Recurrent Prostate CancerNational analysisReview closedCAG-00064NUpdated Sep 14, 2026
- Cryosurgery Ablation for Prostate CancerNational analysisReview closedCAG-00031NUpdated Sep 14, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "Advia Centaur Psa", any status and sponsor, newest update first.
No registered device study names "Advia Centaur Psa".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Advia Centaur Psa", and for the whole product code for context.
This brand
3 reports: 3 malfunction, 0 injury, 0 death
Whole product code MTF
390 reports: 373 malfunction, 17 injury, 0 death
Newest reports for this brand
- ADVIA CENTAUR PSA ASSAYMalfunction
SIEMENS HEALTHCARE DIAGNOSTICS, INC.
1219913-2022-00409 · Received Dec 2, 2022 · Event dated Nov 13, 2022
Device type: Prostate-Specific Antigen (Psa) For Management Of Prostate Cancers (LTJ)
Device problem as coded: High Test Results
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- ADVIA CENTAUR PSA ASSAYMalfunction
SIEMENS HEALTHCARE DIAGNOSTICS, INC.
1219913-2016-00075 · Received Apr 29, 2016 · Event dated Apr 3, 2016
Device type: Total, Prostate Specific Antigen (Noncomplexed & Complexed) For Detection Of Prostate Cancer (MTF)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: No Known Impact Or Consequence To Patient
- ADVIA CENTAUR PSA ASSAYMalfunction
SIEMENS HEALTHCARE DIAGNOSTICS, INC.
1219913-2015-00142 · Received Sep 16, 2015 · Event dated Aug 21, 2015
Device type: Total, Prostate Specific Antigen (Noncomplexed & Complexed) For Detection Of Prostate Cancer (MTF)
Device problem as coded: Incorrect, Inadequate or Imprecise Result or Readings; Incorrect Or Inadequate Test Results
Patient problem as coded: No Known Impact Or Consequence To Patient
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- ADVIA Centaur PSA Assay; Cat No. 06574155/SMN 10310292 (100 test)/02676506/SMN 10310293 (500 test)Terminated
Siemens Healthcare Diagnostics, Inc
Z-2742-2016 · Started Aug 9, 2016
Reason given: Communication provided to emphasize that the PSA values should be interpreted in accordance with current clinical guidelines for defining biochemical recurrence following radical prostatectomy.
Cause as FDA categorized it: Under Investigation by firm · Device type: Prostate-Specific Antigen (Psa) For Management Of Prostate Cancers (LTJ)
Published research
The most relevant PubMed records for "Advia Centaur Psa"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code MTF.
- Elecsys total PSA, total PSA CalSet IIRoche Diagnostics Corp. · PMA 2023
- ARCHITECT Total PSA, Alinity i Total PSAAbbott Laboratories · PMA 2023
- Access Hybritech PSABeckman Coulter, Inc. · PMA 2024
- Dimension Vista Tpsa AssaySiemens Healthcare Diagnostics · PMA 2016
- Atellica IM Total PSA II (tPSAII)Siemens Healthcare Diagnostics, Inc. · PMA 2026
- Axsym Total PsaAbbott Laboratories · PMA 2011
- Abbott Architect Total PsaAbbott Laboratories · PMA 2011
- Immulite/Immulite 1000/IMMULITE 2000/IMMULITE 2500 Psa & 3RD Generation PsaSiemens Healthcare Diagnostics, Inc. · PMA 2010
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.